Simple and selective spectrophotometric assay of diethylcarbamazine citrate using 2,3-dichloro-5,6-dicyano-p-benzoquinone and 2,4-dinitro phenol by Swamy, N. & Basavaiah, K.
Quim. Nova, Vol. 38, No. 5, 715-722, 2015
N
ot
a 
T
éc
ni
ca
http://dx.doi.org/10.5935/0100-4042.20150061 
*e-mail: kanakapurabasavaiah@gmail.com
SIMPLE AND SELECTIVE SPECTROPHOTOMETRIC ASSAY OF DIETHYLCARBAMAZINE CITRATE USING 
2,3-DICHLORO-5,6-DICYANO-p-BENZOQUINONE AND 2,4-DINITRO PHENOL
Nagaraju Swamy and Kanakapura Basavaiah* 
Department of Chemistry, Manasagangothri, University of Mysore, Mysore-570 006, Karnataka, India
Recebido em 09/10/2014; aceito em 02/02/2015; publicado na web em 14/04/2015
Two simple, rapid and inexpensive spectrophotometric methods are described for the determination of diethylcarbamazine citrate 
(DEC) in bulk drug and formulations. The methods are based on the charge–transfer (CT) complexation reaction involving DEC as the 
n- donor and 2,3-dichloro-5,6-dicyano-p-benzoquinone [DDQ] (method A) and 2,4-dinitro phenol [DNP] (method B) as π-acceptors 
in chloroform. The absorbance of CT complexes was measured at 480 nm for method A, and 420 nm for method B. Under optimum 
conditions, Beer’s law was obeyed over the concentration ranges 4-90 and 4-100 µg mL-1 for methods A and B, respectively. 
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INTRODUCTION
Diethylcarbamazine citrate (DEC), chemically known as [N, 
N-diethyl-4-methyl-1-piperazinecarboxamide citrate] is an anthel-
mintic agent used in the treatment of filarial infections caused by a 
host of organisms commonly found in the tropics.1 It is also the alter-
native drug of choice in Onchocerca volvulus infections and tropical 
eosinophilia.2 The drug is official in British Pharmacopoeia (BP),3 
which describes a non-aqueous titration method for its determination 
and also in the United States Pharmacopoeia (USP)4 which uses a 
liquid chromatographic technique with phosphate buffer-methanol 
system as the mobile phase for the assay with uv detection at 220 nm. 
Other than these official methods, several methods have been 
reported for the determination of DEC in pharmaceutical dosage 
forms, and include gas chromatography (GC),5-8 high performance 
liquid chromatography (HPLC),9-11 proton magnetic resonance (PMR) 
spectroscopy,12,13 DC polarography,14 ion selective electrode poten-
tiometry15 and titrimetry.16,17 However, many of the reported methods 
for DEC, particularly, the chromatographic methods are complex, 
requiring expensive instrumental set up and skilled operator which 
are not always found in laboratories of developing and under deve-
loped countries. Thus, the need for a simple, selective and low-cost 
method is obvious, especially for routine quality control analysis of 
pharmaceuticals containing DEC.
Several spectrophotometric methods based on diverse chemical 
reactions are found in the literature for DEC. Charge-transfer com-
plex formed with iodine was used by Wahbi et al.18 for the assay of 
1-6 µg mL–1 DEC in tablets. Chloranilic acid has been employed 
by two groups of workers19,20 whereas picric acid was used by 
Ramachandran21 as CT complexing agent for the assay of drug in 
pharmaceuticals based on the same type of reaction. In a method 
reported by Basu and Dutta,22 the ion associate formed by DEC with 
ammonium reineckate at pH 3.5 was filtered, dissolved in acetone and 
absorbance measured at 525 nm. The colored condensation product23 
formed by malonic acid with acetic anhydride in the presence of DEC 
was measured at 333 nm facilitating the assay of the drug in dosage 
forms. In a similar method,24 the base form of the drug was reacted 
with malonic acid and acetic anhydride at 80 oC for 30 min and the 
resulting condensation product was measured at 334 nm. The yellow 
colored condensation product25 formed by an acetous solution of 
DEC with acetic anhydride-pyridine mixture was measured at 428 
nm and used for the determination of DEC in 10-100 µg mL–1 range 
in commercial tablets. 
There are three reports on the use of ion-pair complexation 
reactions for the spectrophotometric assay of DEC. Rao and 
Subramanyam26 employed bromophenol blue at acidic pH as the ion 
pair complexing agent for the determination of the drug in tablets 
and biological fluids. The drug in tablets, syrups and parenterals was 
determined by extracting the ion-pair complex formed with bromocre-
sol green27 at pH 4.6 with chloroform. The colored complexes of the 
drug with Fast green FCF at pH 5.0 and orange II in 0.1 mol L-1 HCl 
were successfully employed by Sastry et al.,28 for the determination 
of DEC in bulk drug and pharmaceutical preparations by extractive 
spectrophotometry. 
The reported spectrophotometric methods suffer from one or 
the other disadvantage such as poor sensitivity and narrow linear 
range,18-20 use of critical pH condition,22-28 heating,23-25 tedious and 
time consuming steps like precipitation, filtration and washing,23 and 
extraction.26-28 Hence, there is a need for developing a method free 
from such disadvantages.
The aim of the present study was to develop and validate two 
simple, rapid, sensitive, cost-effective and extraction-free spectro-
photometric methods based on charge-transfer (CT) complexation 
reactions using DDQ and DNP as π-acceptors. In both the methods, 
drug is reacted with DDQ and DNP in chloroform to form orange/
yellow colored CT complexes with absorption maxima peaking at 
480 and 420 nm, respectively. The methods were successfully applied 
to quantify DEC in pharmaceutical formulations. 
EXPERIMENTAL
Apparatus
A Systronics model 166 digital spectrophotometer (Systronics, 
Ahmedabad, Gujarat, India) equipped with 1-cm matched quartz cells 
was used for all absorbance measurements.
Materials
Pharmaceutical grade DEC (99.7% pure) was procured from 
Inga Laboratories Pvt. Ltd., Mumbai, India, and was used as re-
ceived. Banocide Forte tablets (Glaxo Smith Kline Pharma. Ltd., 
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Nashik, India) and Banocide syrup (Glaxo Smith Kline Pharma. Ltd., 
Bangalore, India) both were purchased from local commercial stores. 
Reagents and chemicals
All reagents used were of analytical reagent grade and spectro-
scopic grade organic solvents were used throughout the investigation.
A 0.1% DDQ (Avra Syntheis Pvt. Ltd., Hyderabad, India), and 
0.4% DNP (S.D. Fine Chem., Mumbai, India) solutions were prepared 
separately in chloroform (CHCl3) (Merck Ltd., Mumbai, India) for 
method A, and method B, respectively.
Standard DEC base solution [200 mg mL-1]
An amount of the powdered salt equivalent to 10 mg DEC base 
was accurately weighed and dissolved in 10 mL water in a 125 mL 
separatory funnel. The solution was made alkaline by adding 10 mL 
of 1 mol L-1 NaOH and shaken successively for 2 min with three 
10 mL portions of CHCl3, each extract was pooled in a beaker and 
passed through 2 g of anhydrous sodium sulphate supported on a 
quantitative filter paper using small funnel in to a 50 mL calibrated 
flask and completed to the mark with CHCl3. 
ASSAY PROCEDURES
Method A (Using DDQ)
Different aliquots of 0.1, 0.25, 0.5, 1.0, 1.5, 2.0, and 2.25 mL of 
standard DEC base solution (200 mg mL-1) were accurately transferred 
to 5 mL calibrated flasks using a micro burette, and the total volume 
was adjusted to 2.5 mL by adding adequate quantity of CHCl3 and 
0.75 mL of 0.1% DDQ was added to each flask and the mixture was 
diluted to the volume with CHCl3 and mixed well. The absorbance 
of each solution was measured at 480 nm against a reagent blank 
within 10 min.
Method B (Using DNP)
Varying aliquots of 0.1, 0.25, 0.5, 1.0, 1.5, 2.0 and 2.5 mL of 
standard DEC base solution (200 mg mL-1) were accurately added to 
5 mL standard flasks using a micro burette, and the total volume was 
adjusted to 2.5 mL with CHCl3. One mL of 0.4% DNP was added 
to each flask and the mixture was diluted to the volume with CHCl3 
and mixed well. After 5 min, the absorbance of each solution was 
measured at 420 nm against a reagent blank prepared simultaneously.
A standard graph was constructed by plotting absorbance against 
concentration, and the unknown concentration was computed from 
the regression equation derived using Beer’s law data.
Procedure for tablets
Ten tablets each containing 100 mg DEC was weighed accurately 
and ground into a fine powder. An accurately weighed quantity equi-
valent to 10 mg of DEC base was dissolved in 10 mL water in a beaker 
and filtered to remove the insoluble matter. The residue was washed 
with water, the washings along with the filtrate were transferred to 
a 125 mL separatory funnel and the base solution was prepared as 
described earlier. Appropriate aliquots were then subjected to analysis 
following the above procedures.
Procedure for syrup
The content of five 100 mL bottle syrup was pooled and 5 mL 
syrup was diluted with water to 50 mL, and 5 mL of the resulting 
dilute syrup was pipetted out into a 125 mL separating funnel 
and mixed with 10 mL water. Shaken for 2 minutes with 10 mL 
1 mol L-1 NaOH and three 10 mL portions of chloroform, and the 
base were extracted as described under ‘standard DEC base so-
lution’. This 240 mg mL-1 syrup extract was further diluted to get 
working standard solution of 200 mg mL-1 with CHCl3 and used in 
the assay.
RESULTS AND DISCUSSION
Charge-transfer complexes arise from a donor-acceptor mecha-
nism of Lewis acid-base reaction between two or more different 
chemical constituents. The formation of electron donor acceptor 
complexes can be assessed for their validity as a simple quantitative 
analytical method for many drug substances which can act as elec-
tron donors. DDQ and DNP as π- acceptors have been successfully 
employed in the determination of a variety of electron donating basic 
compounds of pharmaceutical importance.29-38
Absorption spectra
The reaction of DDQ or DNP with DEC base, results in the 
formation of intense orange or yellow colored product. The absorp-
tion of colored products was recorded at 380-500 nm against the 
corresponding reagent blanks. The resulting colored charge-transfer 
complexes showed maximum absorbance at 480 nm and 420 nm 
for DEC base-DDQ (Figure 1) and DEC base-DNP (Figure 2), 
respectively.
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Figure 1. Absorption spectra of DEC base-DDQ complex (-▲-) [40 µg mL-1 
DEC] and blank (-  -)
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Figure 2. Absorption spectra of DEC base-DNP complex (-▲-) [80 µg mL-1 
DEC] and blank (-  -)
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Reaction mechanism
The reaction involved in the present methods is the charge-transfer 
complex formed by the electronic transition to an excited state where 
the transfer of electronic charge from donor to acceptor moiety takes 
place partially. As a result, the transition in this excitation energy 
occurs very frequently in the visible region of the electromagnetic 
spectrum.39 DEC base reacts with DDQ or DNP yielding orange or 
yellow colored chromogen that exhibits a maximum absorption at 480 
nm or 420 nm in chloroform. This can be attributed to the formation 
of charge-transfer complex between DEC base (as n-donor), DDQ and 
DNP (as π-acceptors) followed by the formation of radical anion due 
to the dissociation of DEC base-DDQ/DNP complex in chloroform. 
The interaction between the donor and acceptor occurs according to 
the Schemes 1 and 2.
Choice of solvent
DEC is soluble in water, hot alcohol and practically insoluble 
in most organic solvents, and hence the drug was converted into 
base form using sodium hydroxide and extracted into CHCl3 before 
reacting with DDQ or DNP. For preparation of the reagent solutions, 
attempts were made to use different solvents such as 1,4-dioxan, 
CHCl3, acetonitrile, acetone, t-butanol, 2-propanol and dichlorome-
thane, and the reaction of DEC base with DDQ or DNP was followed. 
In both the methods, CHCl3 was best suited for preparation of DEC 
base, and DDQ and DNP solutions. Similarly, the effect of the diluting 
solvent was studied and the results showed that the ideal diluting 
solvent to achieve maximum sensitivity was CHCl3.
Effect of reagent concentration
Though, 0.5 mL of 0.1% DDQ was found adequate in method A 
(Figure 3), in order to achieve greater stability of the colored species, 
0.75 mL of 0.1% DDQ was used; and 1.0 mL of 0.4% DNP gave 
maximum absorbance in method B (Figure 4). Larger volumes were 
unsuitable because of increasing blank absorbance values.
Reaction time and stability
In method A, although the complex (DEC base:DDQ) was for-
med instantaneously, constant absorbance readings were obtained 
after not less than 60 min of standing time at ambient temperature 
(28±2 ºC) and remained constant for at least 24 h (Figure 5), hence, 
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Scheme 2. Reaction mechanism for the formation of DEC base-DNP CT complex (method B)
N
N
N
O
+
O
O
CN
CN
Cl
Cl
DECbase
DDQ
CT Complexation
N
N
N
O
O
O
CN
CN
Cl
Cl
DEC DDQ+
DDQ radical anion
measured at 480 nm
1:1 DEC base-DDQ complex
Scheme 1. Reaction mechanism for the formation of DEC base-DDQ CT complex (method A)
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Figure 3. Effect of volume of 0.1% DDQ (Method A)
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Figure 4. Effect of volume of 0.4% DNP (Method B)
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in order to avoid a standing time of 60 min, absorbance were mea-
sured within 5 min. 
Complete color development of the DEC base:DNP complex 
was attained immediately in method B, and the colored species were 
stable for at least 24 h (Figure 6).
Composition of the CT complexes
The composition of the CT complexes was established by 
the Job’s method of continuous variations40 using equimolar 
concentrations of the drug (base form) and reagents (1.003×10-3 
mol L–1 in both methods). The results indicated that a 1:1 (drug: 
dye) complex is formed in both methods, shown in Figure 7 and 
Figure 8.
METHOD VALIDATION
A linear correlation was found between the absorbance at λmax 
and the concentration of DEC (Figure 9) in the ranges given in Table 
1. Regression analysis of the Beer’s Law data using the least squares 
method was performed to evaluate the slope (b), intercept (a) and the 
correlation coefficient (r) for each system and the values are presented 
in Table 1. The optical characteristics such as the limits of the Beer 
Law, molar absorptivity and the Sandell sensitivity values of both 
methods are also given. In addition, the limits of detection (LOD) 
and quantification (LOQ), calculated according to ICH guidelines41 
are also compiled in Table 1. As can be seen from Table 1, the values 
of slope indicate moderate sensitivity of the methods, and low values 
of intercept imply nearly perfect adherence to the Beer’s law. Further, 
low values of standard deviation of slope and intercept indicate that 
the points tend to be very close to the expected values. 
Precision and accuracy
For three levels of analyte, the assays were repeated seven times 
within the day to determine the intra-day precision and five times on 
different days to determine the inter-day precision of the methods. 
The percentage relative standard deviation (RSD) values were ≤1.54% 
(intra-day) and ≤2.13% (inter-day), indicating the high precision of 
the methods. The accuracy was evaluated as the percentage relative 
error (RE) between the measured mean concentrations and the taken 
concentrations for DEC. The RE values of ≤2.25% demonstrate the 
high accuracy of the proposed methods as shown in Table 2.
Selectivity study
Selectivity was determined by using placebo blank and synthetic 
mixture analysis. A placebo blank, consisting of starch (20 mg), 
acacia (15 mg), hydroxyl cellulose (25 mg), sodium citrate (30 mg), 
talc (20 mg), magnesium stearate (25 mg) and sodium alginate (25 
mg) was prepared by thorough mixing and its solution was prepared 
as described under “procedure for tablets”, and then subjected to 
analysis. The absorbance of the placebo blank was almost equal 
to the absorbance of the reagent blank suggesting no interference.
A synthetic mixture was prepared by adding 10 mg of pure 
DEC to about 12 mg of the above mentioned placebo blank, and the 
mixture was homogenized. Following the same procedure for tablets, 
the synthetic mixture solution was prepared, and a suitable aliquot 
Figure 5. Stability of DEC base-DDQ complex in method A
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Figure 6. Stability of DEC base-DNP complex in method B
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Figure 7. Job’s plot for DEC base-DDQ complex (1.003×10-3 M solutions of 
DEC base and DDQ in method A)
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Figure 8. Job’s plot for DEC base-DNP complex (1.003×10-3 M solutions of 
DEC base and DNP in method B)
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was subjected to analysis by both methods (n=5), after appropriate 
dilution. The percent recoveries of DEC were 98.1±1.5 and 101.4±2.1 
for methods A and B respectively. This confirms the selectivity of the 
methods in presence of common excipients.
Robustness and ruggedness
The robustness of the methods was evaluated by making small 
incremental changes in the volume of reagent (0.75±0.2 mL of DDQ; 
1±0.2 mL of DNP) and contact time (1±0.2 min in both methods A 
and B), and the effect of the changes was studied on the absorbance 
of the complex systems. The changes had negligible influence on the 
results as revealed by small intermediate precision values expressed 
as RSD % (≤ 3%). Method ruggedness was demonstrated by having 
the analysis performed by four analysts, and by a single analyst 
performing the analysis on four different instruments in the same 
laboratory. The intermediate precision values (RSD) in both instances 
were in the range 0.93-2.98%, indicating acceptable ruggedness as 
indicated in Table 3.
Applications
The proposed methods were applied for the determination of 
DEC in commercial formulations. The results were compared with 
those obtained by the US Pharmacopoeia method.5 Statistical analy-
sis of the results did not detect any significant difference between 
the performance of the proposed methods and official method with 
respect to accuracy and precision as revealed by the Student’s t- and 
variance ratio F-values as shown in Table 4. 
Recovery studies
The recovery test was performed by spiking the pre-analyzed 
commercial formulations with pure DEC at three different levels 
(50, 100 and 150% of the content taken) and the total was found by 
the proposed methods. Each test was repeated three times. In both 
the cases, the recovery values ranged between 98.40 and 102.8%, 
with a standard deviation in the range 0.59–1.84%. The closeness of 
the results to 100% showed the fairly good accuracy of the methods 
(Table 5).
Table 1. Sensitivity and regression parameters
Parameter Method A Method B
λmax, nm 480 420
Color stability, hr. > 24 > 24
Linear range, µg mL-1 4–90 4–100
Molar absorptivity (ε), L mol-1 cm-1 1.88×103 2.05×103
Sandell sensitivity*, µg cm-2 0.1061 0.0975
Limit of detection (LOD), mg mL-1 0.21 0.22
Limit of quantification (LOQ), 
mg mL-1
0.63 0.67
Regression equation, Y**
Intercept (a) (7.5±0.94)×10-2 (2.4±0.91)×10-2
Slope (b) (12±0.16)×10-3 (8.6±0.16)×10-3
Regression coefficient (r) 0.9996 0.9991
*Limit of determination as the weight in µg mL-1 of solution, which corre-
sponds to an absorbance of A = 0.001 measured in a cuvette of cross-sectional 
area 1 cm2 and l = 1 cm. **Y=a+bX, Where Y is the absorbance, X is con-
centration in µg mL-1, a is intercept and b is slope.
Table 2. Evaluation of intra-day and inter-da-y accuracy and precision
Method DEC taken (µg mL-1)
Intra-day accuracy and precision (n=7) Inter-day accuracy and precision (n=7)
DEC founda  
(µg mL-1)
RSDb 
%
REc 
%
DEC found 
(µg mL-1)
RSDb 
%
REc 
%
A
40.0 
60.0 
80.0
40.7 
59.2 
81.2
1.45 
1.18 
0.95
1.70 
1.34 
1.50
40.9 
61.2 
81.4
1.68 
1.43 
1.29
2.25 
2.01 
1.75
B
40.0 
60.0 
80.0
39.46 
60.91 
79.10
1.54 
0.96 
1.42
1.36 
1.52 
1.12
40.6 
60.93 
81.1
1.59 
2.13 
1.81
1.62 
1.55 
1.37
aMean value of 7 determinations; bRelative standard deviation (%); cRelative error (%).
Figure 9. Calibration plot: (a) Method A and (b) Method B
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CONCLUSIONS
The proposed methods make use of simple reagents and instru-
ment which an ordinary analytical laboratory can afford; the methods 
are rapid, extraction-free, cost-effective and do not involve any criti-
cal reaction conditions. The suggested methods utilize a single step 
reaction and single solvent. The proposed methods are accurate and 
precise, and free from interference caused by the excipients expected 
to be present in dosage forms. The method was demonstrated to be 
both robust and rugged. The methods offer several advantages over 
the existing methods in terms of sensitivity, selectivity, linear dynamic 
range and mild optimum conditions as indicated in Table 6 and also 
many advantages over the other techniques, such as HPLC, GC and 
PMR such as reduced cost, and speed with high accuracy. Hence, 
the methods can be used in the routine analysis of drugs in quality 
control laboratories.
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Table 3. Method robustness and ruggedness expressed as intermediate precision
Method DEC taken (µg mL-1)
Method robustness Method ruggedness
Parameters altered
Inter-analysts 
(%RSD), (n=4)
Inter-instruments 
(%RSD), (n=4) Volume of DDQ / DNP mLa  
%RSD (n=3)
Reaction timeb 
%RSD (n=3)
A
40.0 1.26 1.12 1.35 1.63
60.0 1.78 1.25 2.05 1.84
80.0 2.09 1.13 2.12 2.98
B
40.0 0.93 1.27 1.12 1.36
60.0 1.85 1.08 0.96 1.21
80.0 1.52 2.09 1.89 2.35
aIn method A, the volumes of reagent were 0.75±0.2 mL and in method B, the volumes were 1±0.2. bThe reaction times were 1±0.2 min in both methods.
Table 4. Results of analysis of formulations by the proposed methods
Formulation analyzed Label claim
Found* (Percent of label claim±SD)
Official method
Proposed methods
Method A Method B
Banocide Forte tablets 100 mg per tablet 99.3±1.27
100.9±0.93 101.6±1.54
t = 2.28 t = 2.58
F = 1.86 F = 1.47
Banocide syrup 120 mg per 5 mL 102.4±1.09
103.5±1.13 102.9±1.74
t = 1.57 t = 0.79
F = 1.07 F = 1.12
*Mean value of five determinations. Tabulated t-value at the 95% confidence level is 2.77. Tabulated F-value at the 95% confidence level is 6.39.
Table 5. Results of recovery study via standard addition technique 
Method Formulation 
studied
DEC in formulation, 
µg mL-1
Pure DEC added, 
µg mL-1
Total found, 
µg mL-1
Pure DEC recovered* 
Percent±SD
A
Banocide Forte 
tablets
20.18 
20.18 
20.18
10 
20 
30
30.09 
40.26 
50.48
99.7±1.54 
100.2±0.98 
100.6±1.59
Banocide syrup
20.70 
20.70 
20.70
10 
20 
30
31.40 
41.47 
52.32
102.3±1.52 
101.9±0.97 
103.2±0.59
B
Banocide Forte 
tablets
20.32 
20.32 
20.32
10 
20 
30
29.84 
40.76 
49.91
98.4±1.49 
101.1±1.19 
99.2±0.54
Banocide syrup
20.58 
20.58 
20.58
10 
20 
30
30.98 
41.72 
52.40
101.3±1.84 
102.8±0.89 
103.6±154
*Mean value of three determinations.
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Table 6. Comparison of performance of the present methods with the existing methods
Sl. No. Reagent/s used Methodology λmax (nm)
Linear range 
 (mg mL-1) 
ε (L mol-1cm-1)
Remarks Ref. No.
1 *CAA Measurement of purple color CT 
complex in dioxane-CHCl3
540 10-400 Mixture of organic solvents used 21
2 Picric acid Yellow color CT complex mea-
sured in alcohol - - - 22
3 Ammonium  
reineckate
Absorbance of red color product at 
pH=3.5 in acetone measured 525 -
Tedious & time consuming, Pptn 
washing and dissolution steps in-
volved
23
4 Malonic acid-acetic 
anhydride
Measurement of absorption of 
condensation product 333 -
Heating step and longer contact time 
involved 25
5 HOAc-Ac2O and pyridine
Absorbance of yellow color prod-
uct measured 428 10-110
Heating step and longer contact time 
involved 26
6 *BPB Extracted ion-pair complex mea-
sured - -
Tedious and time consuming extrac-
tion step and critical pH adjustment 
involved
27
7 *BCG Yellow ion-pair complex measured in chloroform - -
Tedious and time consuming extrac-
tion step and critical pH adjustment 
involved
28
8 a) Fast green FCF b) Orange-II
Ion-pair complex extracted into 
chloroform and measured - -
Tedious and time consuming extrac-
tion step and critical pH adjustment 
involved
29
9
a) *DDQ 
b) *DNP
Measurement of CT complex in 
chloroform 
Absorbance of yellow color CT 
complex measured
480 
420
4–90 
1.88×103 
 
4–100 
2.05×103
Rapid, no heating or extraction step 
involved, sensitive, wide linear dy-
namic range
Present work
*CAA-chloranilic acid, BCG-bromocresol green, BPB-bromophenol blue, DDQ-2,3-dichloro, 5,6-dicyano-p-benzoquinone and DNP-2,4 -dinitro phenol.
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